| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | VDP |
| Uniprot No | O60763 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-962aa |
| 氨基酸序列 | MNFLRGVMGGQSAGPQHTEAETIQKLCDRVASSTLLDDRRNAVRALKSLSKKYRLEVGIQAMEHLIHVLQTDRSDSEIIGYALDTLYNIISNEEEEEVEENSTRQSEDLGSQFTEIFIKQQENVTLLLSLLEEFDFHVRWPGVKLLTSLLKQLGPQVQQIILVSPMGVSRLMDLLADSREVIRNDGVLLLQALTRSNGAIQKIVAFENAFERLLDIISEEGNSDGGIVVEDCLILLQNLLKNNNSNQNFFKEGSYIQRMKPWFEVGDENSGWSAQKVTNLHLMLQLVRVLVSPTNPPGATSSCQKAMFQCGLLQQLCTILMATGVPADILTETINTVSEVIRGCQVNQDYFASVNAPSNPPRPAIVVLLMSMVNERQPFVLRCAVLYCFQCFLYKNQKGQGEIVSTLLPSTIDATGNSVSAGQLLCGGLFSTDSLSNWCAAVALAHALQENATQKEQLLRVQLATSIGNPPVSLLQQCTNILSQGSKIQTRVGLLMLLCTWLSNCPIAVTHFLHNSANVPFLTGQIAENLGEEEQLVQGLCALLLGISIYFNDNSLESYMKEKLKQLIEKRIGKENFIEKLGFISKHELYSRASQKPQPNFPSPEYMIFDHEFTKLVKELEGVITKAIYKSSEEDKKEEEVKKTLEQHDNIVTHYKNMIREQDLQLEELRQQVSTLKCQNEQLQTAVTQQVSQIQQHKDQYNLLKIQLGKDNQHQGSYSEGAQMNGIQPEEIGRLREEIEELKRNQELLQSQLTEKDSMIENMKSSQTSGTNEQSSAIVSARDSEQVAELKQELATLKSQLNSQSVEITKLQTEKQELLQKTEAFAKSVEVQGETETIIATKTTDVEGRLSALLQETKELKNEIKALSEERTAIKEQLDSSNSTIAILQTEKDKLELEITDSKKEQDDLLVLLADQDQKILSLKNKLKDLGHPVEEEDELESGDQEDEDDESEDPGKDLDHI |
| 预测分子量 | 107,8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于VDP(病毒样颗粒，Virus-like Particles)重组蛋白领域的示例文献(内容为模拟概括)：
1. **《Engineering of Chimeric Virus-like Particles for Targeted Drug Delivery》**
- 作者：Smith J, et al.
- 摘要：研究利用重组技术构建嵌合型VDP，通过表面修饰实现靶向肿瘤细胞的药物递送，证明其在体外和小鼠模型中显著提高药物靶向效率。
2. **《Expression and Purification of HPV L1 Protein in Yeast for VLP Vaccine Development》**
- 作者：Zhang L, et al.
- 摘要：报道在酵母系统中高效表达HPV L1重组蛋白并自组装成VLP，动物实验显示其诱导强效中和抗体，为低成本HPV疫苗开发提供方案。
3. **《A Modular Platform for Rapid Assembly of Multivalent Viral Nanoparticles》**
- 作者：Kim H, et al.
- 摘要：提出模块化VDP重组蛋白设计策略，通过抗原表位灵活展示构建多价疫苗，成功应用于流感病毒和HIV的广谱免疫原开发。
4. **《Biosensor Applications of Engineered Viral Capsid Proteins》**
- 作者：Wang Y, et al.
- 摘要：利用重组VDP作为生物传感器载体，通过荧光标记和抗原结合域改造，实现高灵敏度检测血液中的疾病标志物。
注：以上为示例文献，实际研究请通过PubMed、Web of Science或Google Scholar检索关键词"VLP recombinant protein"、"virus-like particle engineering"获取最新论文。
**Background of VDP Recombinant Proteins**
Recombinant proteins, engineered through genetic modification, are produced by inserting target gene sequences into host organisms (e.g., bacteria, yeast, or mammalian cells) to express specific proteins. Viral-derived protein (VDP) recombinant technology focuses on producing viral proteins or their subunits using these systems, enabling scalable and safe alternatives to traditional methods like live-virus cultivation. This approach gained prominence in the late 20th century with advancements in molecular biology, particularly for vaccine development and therapeutic research.
VDP recombinant proteins are pivotal in addressing global health challenges. For example, hepatitis B vaccines utilize recombinant viral surface antigens, avoiding infectious risks. Similarly, during the COVID-19 pandemic, recombinant spike proteins of SARS-CoV-2 were critical in subunit vaccine development. Beyond vaccines, these proteins serve as tools for diagnostics (e.g., ELISA kits), antiviral drug screening, and structural studies to understand viral mechanisms.
The technology’s flexibility allows customization, such as incorporating fusion tags for purification or enhancing immunogenicity through adjuvants. Challenges remain in optimizing expression yields, ensuring proper post-translational modifications (e.g., glycosylation), and maintaining conformational stability for functional efficacy. Innovations in cell-line engineering, CRISPR, and AI-driven protein design are addressing these limitations.
Overall, VDP recombinant proteins represent a cornerstone of modern biotechnology, balancing safety, scalability, and precision for applications in medicine and research. Their continued evolution supports rapid responses to emerging pathogens and personalized therapeutic strategies.
(Word count: 248)
×
